A Phase 3, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 (PE34) Process Administered Concomitantly with M-M-R II

Project: Other project

StatusFinished
Effective start/end date8/21/178/20/19

Funding

  • Merck Sharp & Dohme Corporation: $63,118.44